[Raynaud's phenomenon after chemotherapy. Apropos of 3 cases].
Raynaud's phenomenon is studied in three patients after cancer chemotherapy. In these cases, Raynaud's phenomenon occurs as: a true coincidence, a secondary complication of which neoplastic biological signs are thrombocythemia, hyperfibrinemia, immune complexes, cryoglobulinemia..., a therapeutic implication. The rate of therapeutic implication is difficult to precise. Raynaud's phenomenon is a little symptom over a severe illness. Several drugs are responsible for this fact. A literature review mentions Vincristine, Bleomycin, Cisplatin... For our three patients as in the literature review the tumoral nature is less important than the drug type. For us Bleomycin alone as in association is able to induce Raynaud's phenomenon. The occurrence of single Raynaud's phenomenon may be a systemic scleroderma is first sign. However it is important to affirm the true single Raynaud's phenomenon. In this case there is a lack of signs: scleroderma may be paraneoplastic, drugs may be pulmonary toxic, anticentromere antibodies may be positive during antineoplastic treatment. The pathogenesis for Raynaud phenomenon drug induction is unknown. For Bleomycin action the role of skin concentration, fibroblastic lesion, and vascular disturbance is discussed.
D
D
Adoue
P
P
Arlet
C
C
Vilain
Y
Y
Le Tallec
J L
JL
Bonafé
B
B
de Lafontan
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007866:Leg; D008223:Lymphoma / Q000188:drug therapy; D008875:Middle Aged; D011928:Raynaud Disease / Q000139:chemically induced* / Q000503:physiopathology; D012514:Sarcoma, Kaposi / Q000188:drug therapy
D001761:Bleomycin
Phénomène de Raynaud après chimiothérapie. A propos de 3 observations.